Real Psychiatry: A Live Virtual Educational Experience Designed for and by Advanced Practice Professionals on the Frontlines of Modern Practice
Mental health disorders have long been a leading contributor to global disease burden, but several years marked by pandemic have led to a spike in prevalence, the effects of which may be palpable well into the future. In this milieu, of and demand for advanced practice professionals (APPs) in this space has risen exponentially. In particular, nurse practitioners (NPs) from all levels of experience are rising to meet this need. But despite organizations’ increasing efforts to create continuing education for APPs, a recent EfficientCME survey of NPs reveals that their needs and preferences are still not being sufficiently met across most domains including instructional design (e.g., lecture vs case-based) and featured speakers (e.g., physician vs NP). Correspondingly, many NPs feel insufficiently prepared to manage multiple aspects of real psychiatric care.
To help improve the translation from education to practice, EfficientCME and Partners for Advancing Clinical Education (PACE) have created an experience tailored to meet the needs of this group from trainee all the way through early-career and established APPs so that they can better navigate the ever-evolving foundational and practical hurdles of pervasive mental health needs. The full day, virtual psychiatry immersion conference is designed for and by advanced practitioners with an emphasis on hands-on learning and evidence-based clinical implementation.
This activity is intended for advanced practice professionals caring for patients with common psychiatric disorders.
Upon completion of this activity, participants should be able to:
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Welcome Address 8:00 am - 8:10 am (10 min)
Intersecting Indications: The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management 8:10 am - 8:55 am (45 min)
Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics 8:55 am - 9:55 am (60 min)
Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs 10:10 am - 10:35 am (25 min)
The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience 10:35 am - 11:25 am (50 min)
Turning the Tide in Bipolar Depression 11:25 am - 12:10 pm (45 min)
Extrapyramidal Symptoms: When are They Tardive Dyskinesia? 1:10 pm - 1:55 pm (45 min)
The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies 1:55 pm - 2:40 pm (45 min)
Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan 2:50 pm - 3:55 pm (45 min)
Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment 3:55 pm - 4:05 pm (30 min)
Closing Remarks 4:05 pm - 4:15 pm (10 min)
Clinical Professor, Psychiatry and Behavioral Sciences
Psychiatric Mental Health Nurse Practitioner
Alay Health Team / Delke & Dursahl LLC
Mindful Therapy Group
Psychiatric-Mental Health Nurse Practitioner
SPGPM2 Services, LLC
Mountainside Healthcare LLC
Morningstar Family Medicine / Baptist Health System
Springbok Health, Inc
Psychiatric Mental Health Nurse Practitioner
Seaside Behavioral Health
Psychiatric Mental Health Nurse Practitioner
“Phone a Pharmacist” Faculty
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Faculty and Disclosure of Conflicts of Interest
- Consulting Fees: AbbVie, Boehringer Ingelheim, Corium, Eisai, Intra-Cellular, Teva
- Speakers Bureau: AbbVie/Allergan, Alkermes, Intra-Cellular, Teva, US World Meds
Ann Barbaro, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
Leslie Citrome, MD, MPH reported the following relationships:
- Contracted Research: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona
- Consulting Fees: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, and Teva
Bobbi Jo Durst, MSN, APNP, PMHNP- BC has no financial relationships to disclose.
Shannon Eaton, MSN, APN, PMHNP-BC has no financial relationships to disclose.
Christina Fuchs, DNP, PMHNP-BC has no financial relationships to disclose.
Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC has no financial relationships to disclose.
Karen J Greene MSN, Ed, APRN, FNP-C, PMHNP-BC has no financial relationships to disclose.
Amber Hoberg, MSN, APRN, PMHNP-BC reported the following relationships:
- Consulting Fees: Alkermes, Intra-Cellular, Karuna, Neurocrine, Teva
- Spealers Bureau: Acadia, BioXcel, Intra-Cellular, Neurocrine, Otsuka, Teva
Mark Jankelow MSN, BA, PMHNP-BC reported the following relationships:
- Consulting Fees: AbbVie, Alkermes, and Teva
- Speakers Bureau: AbbVie, Alkermes, and Teva
Mia W. Jones, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B reported the following relationships:
- Consulting Fees: AbbVie, Johnson & Johnson, and Teva
- Speakers Bureau: AbbVie, Biogen/Sage, Johnson & Johnson, Neurocrine, and Teva
Chelsea Schwartz, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Efficient LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by independent educational grants from Indivior Inc., Intra-Cellular Therapies, Inc., Teva Pharmaceuticals, and Tris Pharma, Inc.